Closed-loop oxygen usage during invasive mechanical ventilation of pediatric patients (CLOUDIMPP): a randomized controlled cross-over study

The aim of this study is the evaluation of a closed-loop oxygen control system in pediatric patients undergoing invasive mechanical ventilation (IMV). Cross-over, multicenter, randomized, single-blind clinical trial. Patients between the ages of 1 month and 18 years who were undergoing IMV therapy f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in medicine 2024-09, Vol.11, p.1426969
Hauptverfasser: Atakul, Gulhan, Ceylan, Gokhan, Sandal, Ozlem, Soydan, Ekin, Hepduman, Pinar, Colak, Mustafa, Zimmermann, Jan M, Novotni, Dominik, Karaarslan, Utku, Topal, Sevgi, Aǧin, Hasan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of this study is the evaluation of a closed-loop oxygen control system in pediatric patients undergoing invasive mechanical ventilation (IMV). Cross-over, multicenter, randomized, single-blind clinical trial. Patients between the ages of 1 month and 18 years who were undergoing IMV therapy for acute hypoxemic respiratory failure (AHRF) were assigned at random to either begin with a 2-hour period of closed-loop oxygen control or manual oxygen titrations. By using closed-loop oxygen control, the patients' SpO levels were maintained within a predetermined target range by the automated adjustment of the FiO . During the manual oxygen titration phase of the trial, healthcare professionals at the bedside made manual changes to the FiO , while maintaining the same target range for SpO . Following either period, the patient transitioned to the alternative therapy. The outcomes were the percentage of time spent in predefined SpO ranges ±2% (primary), FiO , total oxygen use, and the number of manual adjustments. The median age of included 33 patients was 17 (13-55.5) months. In contrast to manual oxygen titrations, patients spent a greater proportion of time within a predefined optimal SpO range when the closed-loop oxygen controller was enabled (95.7% [IQR 92.1-100%] vs. 65.6% [IQR 41.6-82.5%]), mean difference 33.4% [95%-CI 24.5-42%]; < 0.001). Median FiO was lower (32.1% [IQR 23.9-54.1%] vs. 40.6% [IQR 31.1-62.8%]; < 0.001) similar to total oxygen use (19.8 L/h [IQR 4.6-64.8] vs. 39.4 L/h [IQR 16.8-79]; < 0.001); however, median SpO /FiO was higher (329.4 [IQR 180-411.1] vs. 246.7 [IQR 151.1-320.5]; < 0.001) with closed-loop oxygen control. With closed-loop oxygen control, the median number of manual adjustments reduced (0.0 [IQR 0.0-0.0] vs. 1 [IQR 0.0-2.2]; < 0.001). Closed-loop oxygen control enhances oxygen therapy in pediatric patients undergoing IMV for AHRF, potentially leading to more efficient utilization of oxygen. This technology also decreases the necessity for manual adjustments, which could reduce the workloads of healthcare providers. This research has been submitted to ClinicalTrials.gov (NCT05714527).
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2024.1426969